Mr Jeffrey Francer serves as Vice President, Head of International Regulatory Affairs and Global Regulatory Policy for Eli Lilly and Company. In this role, he leads Lilly’s interactions with regulators and regulatory submissions in the Asia-Pacific, Europe, Middle East, and Africa regions. He also leads Lilly’s U.S. and international regulatory policy and research teams to accelerate access to Lilly’s medicines for patients around the world.

Mr Francer  has led and advised biopharmaceutical companies and policy makers for over 25 years to craft regulatory systems that best meet the needs of patients and improve public health. Prior to joining Lilly in 2023, he served as Senior Vice President, General Counsel, and Interim CEO of the Association for Accessible Medicines, where he managed legal and international trade advocacy for the leading trade association for biosimilar and generic medicines in the U.S. From 2007-2016, Mr Francer served as Vice President and Senior Counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA) where he was the principal counsel to the association on issues relating to the research, development, and regulation of medicines in the U.S. and globally. Prior to joining PhRMA, he served as Associate General Counsel, U.S. Compliance Officer, and Chief Privacy Officer of Biogen Idec, Inc. At Biogen he was the primary in-house counsel on FDA issues, and he led the U.S. corporate compliance program.

Prior to his time in industry, Mr Jeffrey Francer served as Associate Chief Counsel of the U.S. Food and Drug Administration from 2003 to 2005, where he advised agency leaders on issues including clinical investigation, manufacturing compliance, drug promotion, enforcement, and legislative matters.

Mr Francer received his J.D. from the University of Virginia School of Law, in 2000, and his M.P.P. from Harvard University in 1998. He earned his A.B. in Public Policy and Economics from Brown University in 1993. He currently serves on the Board of Directors of Accumulus Synergy, Inc., and he has also served on the Board of the Food and Drug Law Institute (FDLI) and the Editorial Advisory Board of the Food and Drug Law Journal.